EFFECT OF STANDARD INTERFERON AND RIBAVIRIN ON LEUKOCYTE COUNT
AbstractBackground: Chronic Hepatitis C is a public health problems in Pakistan, with 4.5% population infected. It is amenable to antiviral treatment. The ojective of this study was to determine the effect of antiviral treatment on leukocytes count during the treatment of hepatitis C. Methods: In this descriptive case series sixty PCR positive Hepatitis C patients were included and were given standard interferon and ribavirin for a period of six months with a monthly follow up. Total leukocytes were measured at monthly interval to study change in their counts. Results: The mean of baseline leukocytes was compared with the average mean leukocytes of six months treatment, and a decrease of 1603.36/mm3 was observed (p=0.000). Conclusion: Six months treatment of chronic hepatitis C with standard interferon and ribavirin decreases leukocytes count to a significant level.Keywords: Hepatitis C, Interferon, Ribavirin
Hepatitis C World Health Organization. Fact sheet No. 164. Geneva: WHO; 2012. Available Available at:w.who.int/vaccine research/viral cancers. Retrieved on 16-04-2009.
Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P et al. Efficacy and safety of a 2-dose regimens of peg interferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol 2004;99:1298-305.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335–74.
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S2 37-44.
Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473–7.
Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141–51.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358(9286):958-65.
Kontorinis N, Agarwal K, Dieterich DT. Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord 2004;4(Suppl. 1):S39-47.
Soza A, Everhart JE, Glramy MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-79.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.